The combination of imatinib (Gleevec, STI571) and the TKT inhibitor oxythiamine (OT) re-established the sensitivity of chronic myeloid leukemia cells to imatinib. Here, TKT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.